Omalizumab Efficacy in Patients With Refractory Nasal Polyps
Status:
Not yet recruiting
Trial end date:
2023-01-23
Target enrollment:
Participant gender:
Summary
in patients with chronic rhinosinusitis with nasal polyps and concomitant asthma, they have a
poor therapeutic response and a higher recurrence rate, and treatment in these patients often
fails.
investigators conducted this study to survey the efficacy of Omalizumab (anti IgE) on
patients with refractory nasal polyp to confirm its efficacy entering to treatment
guidelines.SNOT-22 score will measure at screening; on day 1; and at weeks 4, 8, 16, and 24
(point range, 0-110, with lower scores indicating better disease control and quality of life
.